相关实验视频
Updated: May 25, 2025

08:09
Generation of Human Brain Organoids for Mitochondrial Disease Modeling
Published on: June 21, 2021
6.0K
在患有线粒体疾病的患者中治疗的治疗方法
1Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yonsei medical journal
|February 25, 2025
概括
线粒体疾病 (MDs) 经常导致. 本综述探讨了线粒体的当前和新兴治疗方法,包括药物,饮食,基因疗法和线粒体移植.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 线粒体医学 线粒体医学
背景情况:
- 线粒体疾病 (MDs) 是一种影响大脑和肌肉等高能量的器官的遗传疾病.
- 是MD中常见的并发症,影响40-60%的患者,并降低生活质量.
研究的目的:
- 审查目前和新兴的治疗方式,以治疗线粒体疾病患者的.
- 突出基因诊断和个性化治疗策略的进展.
主要方法:
- 关于线粒体疾病和治疗的科学文献的综述.
- 讨论抗发作药物,性饮食,基因疗法,线粒体移植,抗氧化剂和线粒体生物发生增强剂.
主要成果:
- 基因测序可以实现精确的MD诊断和量身定制的治疗.
- 抗发作药物和性饮食在减少发作和改善线粒体功能方面表现出有效性.
- 像基因疗法,线粒体移植和抗氧化剂 (例如EPI-743) 等新兴疗法显示出有前途.
结论:
- 包括基因疗法和线粒体移植在内的个性化治疗策略,为改善线粒体的管理提供了希望.
- 了解MD的进展正在为更有针对性和更有效的治疗铺平道路.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
268
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
268
Arteries of the Lower Limbs
176
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
176
Antiepileptic Drugs: GABAergic Pathway Potentiators
307
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
307
Electron Transport Chain: Complex I and II
10.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209
Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22

